Cargando…

Bempedoic acid: A nonstatin drug for the management of hypercholesterolemia

Detalles Bibliográficos
Autores principales:	Govindaraju, Asvitha, Sabarathinam, Sarvesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577242/ https://www.ncbi.nlm.nih.gov/pubmed/34786488 http://dx.doi.org/10.1002/hsr2.431

Ejemplares similares

Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance
por: Laufs, Ulrich, et al.
Publicado: (2019)

Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside
por: Agarwala, Anandita, et al.
Publicado: (2021)

New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia
por: Pirillo, Angela, et al.
Publicado: (2022)

Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis
por: Cicero, Arrigo F. G., et al.
Publicado: (2020)

Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment
por: Sugiyama, Kazutoshi, et al.
Publicado: (2018)

Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia: Systematic Review and Meta‐Analysis of Randomized Controlled Trials
por: Di Minno, Alessandro, et al.
Publicado: (2020)

Bempedoic acid for the treatment of dyslipidemia
por: Marrs, Joel C, et al.
Publicado: (2020)

Bempedoic Acid: for Whom and When
por: Ruscica, Massimiliano, et al.
Publicado: (2022)

Network pharmacology and in silico pharmacokinetic prediction of Ozanimod in the management of ulcerative colitis: A computational study
por: Sivasakthi, Priya, et al.
Publicado: (2022)

Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia
por: Banach, Maciej, et al.
Publicado: (2020)

Role of Bempedoic Acid in Clinical Practice
por: Ballantyne, Christie M., et al.
Publicado: (2021)

Bempedoic acid: what prospective uses?
por: Jacomelli, Ilaria, et al.
Publicado: (2023)

Pharmacokinetics of bempedoic acid in patients with renal impairment
por: Amore, Benny M., et al.
Publicado: (2021)

Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis
por: Tummala, Ramyashree, et al.
Publicado: (2022)

Bempedoic Acid for Lipid Management in the Indian Population: An Expert Opinion
por: Hiremath, Jagdish, et al.
Publicado: (2023)

Correction to: Role of Bempedoic Acid in Clinical Practice
por: Ballantyne, Christie M., et al.
Publicado: (2021)

An Update on New Cholesterol Inhibitor: Bempedoic Acid
por: Kulshreshtha, Mayank
Publicado: (2022)

Severe Hypertriglyceridemia After Use of Bempedoic Acid
por: Bovy, Valentin, et al.
Publicado: (2023)

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy
por: Ballantyne, Christie M, et al.
Publicado: (2019)

New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran
por: Ruscica, Massimiliano, et al.
Publicado: (2021)

Bempedoic Acid, an Inhibitor of Cholesterol Biosynthesis, Reduces Cardiovascular Events
por: Jialal, Ishwarlal, et al.
Publicado: (2023)

A glycemic diet improves the understanding of glycemic control in diabetes patients during their follow-up
por: Sabarathinam, Sarvesh
Publicado: (2023)

Statins and Bempedoic Acid: Different Actions of Cholesterol Inhibitors on Macrophage Activation
por: Linnenberger, Rebecca, et al.
Publicado: (2021)

Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase
por: Bilen, Ozlem, et al.
Publicado: (2016)

Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome
por: Biolo, Gianni, et al.
Publicado: (2022)

Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease
por: Gunn, Laura H., et al.
Publicado: (2022)

Correction: Sugiyama, K.; et al. Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment. Diseases 2018, 6, 44
por: Sugiyama, Kazutoshi, et al.
Publicado: (2018)

Pandemic‐induced stress and obesity leading to abnormal uterine bleeding: A prospective study
por: Preethi, Lakshminarayanan, et al.
Publicado: (2022)

Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins
por: Bays, Harold E., et al.
Publicado: (2021)

Factors Associated With Enhanced Low‐Density Lipoprotein Cholesterol Lowering With Bempedoic Acid
por: Ballantyne, Christie M., et al.
Publicado: (2022)

Beneficial effects of bempedoic acid treatment in polycystic kidney disease cells and mice
por: Hallows, Kenneth R., et al.
Publicado: (2022)

Effects of Bempedoic Acid in Acute Myocardial Infarction in Rats: No Cardioprotection and No Hidden Cardiotoxicity
por: Gergely, Tamás G., et al.
Publicado: (2023)

Bempedoic Acid: An Emerging Therapy for Uncontrolled Low-Density Lipoprotein (LDL) Cholesterol
por: Pradhan, Akshyaya, et al.
Publicado: (2023)

Safety and efficacy of bempedoic acid: a systematic review and meta-analysis of randomised controlled trials
por: De Filippo, Ovidio, et al.
Publicado: (2023)

Antidyslipidemic potential of a novel farnesoid X receptor antagonist in a hamster model of dyslipidemia: Comparative studies of other nonstatin agents
por: Shinozawa, Emiko, et al.
Publicado: (2018)

The effectiveness and value of bempedoic acid and inclisiran for heterozygous familial hypercholesterolemia and secondary prevention of ASCVD: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2021)

National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel Survey
por: Salami, Joseph A., et al.
Publicado: (2018)

CYP3A4 mediated pharmacokinetics drug interaction potential of Maha-Yogaraj Gugglu and E, Z guggulsterone
por: Sabarathinam, Sarvesh, et al.
Publicado: (2021)

KHK, PNPLA3 and PPAR as Novel Targets for the Anti-Steatotic Action of Bempedoic Acid
por: Velázquez, Ana Magdalena, et al.
Publicado: (2022)

Bempedoic Acid: The New Kid on the Block for the Treatment of Dyslipidemia and LDL Cholesterol: A Narrative Review
por: Alam, Uazman, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_60hcde4jjjv294jk6udhfel85k